Cost-efficiency analysis of conversion to biosimilar filgrastim for supportive cancer care and resultant expanded access analysis to supportive care and early-stage HER2+ breast cancer treatment in Saudi Arabia: Simulation study

CONCLUSION: This simulation study demonstrated significant potential cost-savings from biosimilar conversion. These savings provide budget-neutral increased access to supportive and therapeutic cancer care.PMID:36815700 | DOI:10.1080/13696998.2023.2183680

Source: Journal of Medical Economics - February 23, 2023 Category: Health Management Authors: Consuela Cheriece Yousef Mansoor Ahmed Khan Hind Almodaimegh Majed Alshamrani Meteb O Alfoheidy Hana AlAbdalkarim Ahmed AlJedai Anjum Naeem Ivo Abraham Source Type: research